Skip to search formSkip to main contentSkip to account menu

dasabuvir

Known as: Sodium 3-(3-tert-butyl-4-methoxy-5-{6- [(methylsulfonyl)amino]naphthalene-2-yl}phenyl)-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-ide hydrate (1:1:1), N-{6-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl]naphthalen-2-yl}methanesulfonamide, Methanesulfonamide, N-(6-(5-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-3-(1,1-dimethylethyl)-2-methoxyphenyl)-2-naphthalenyl)- 
A non-nucleoside inhibitor of the hepatitis C virus (HCV) non-structural protein 5B (NS5B), an RNA-dependent RNA polymerase, with potential activity… 
National Institutes of Health

Related topics

Related topics

7 relations

Broader (1)

ABT-333
Antiviral AgentsBreast Cancer Resistance Protein Inhibitors [MoA]Hepatitis CUGT1A1 Inhibitors [MoA]

Narrower (1)

dasabuvir sodium monohydrate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Real‐world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
The real‐world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir (PrOD) remain limited for East Asian… 
2017
2017
Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVES
Directly acting antiviral agents (DAA) have been associated with hepatic decompensation, especially in patients with pre… 
2017
2017
Real‐life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong
In registration studies, combination therapy of paritaprevir/ritonavir, ombitasvir, and dasabuvir (PrOD) with and without… 
2017
2017
Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection
Background and AimsOmbitasvir, paritaprevir (given with low-dose ritonavir), and dasabuvir are direct-acting antivirals (DAAs… 
2016
2016
Drug–Drug Interaction of Omeprazole With the HCV Direct‐Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without Dasabuvir
Paritaprevir (administered with low‐dose ritonavir), ombitasvir, and dasabuvir are direct‐acting antiviral agents administered as… 
2016
2016
Cost‐effectiveness of strategy‐based approach to treatment of genotype 1 chronic hepatitis C
The high cost of chronic hepatitis C (HCV) direct‐acting antivirals (DAAs) poses significant financial challenges for health… 
2016
2016
Adding ribavirin to newer DAA regimens does not affect SVR rates in HCV genotype 1 infected persons: results from ERCHIVES
Ribavirin is a key component of several hepatitis C virus (HCV) treatment regimens. However, its utility in combination with… 
2016
2016
Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US
Abstract Objective: This study compared the cost-effectiveness of direct-acting antiviral therapies currently recommended for… 
Review
2015
Review
2015
A 4-drug combination (Viekira Pak) for hepatitis C.
2015
2015
Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir
ABSTRACT The combination of ombitasvir (an NS5A inhibitor), paritaprevir (an NS3/4A inhibitor) coadministered with ritonavir (r… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)